Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.14 USD
Change Today +0.28 / 5.76%
Volume 21.5K
EARS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

auris medical ag (EARS) Snapshot

Open
$4.99
Previous Close
$4.86
Day High
$5.19
Day Low
$4.96
52 Week High
09/12/14 - $7.58
52 Week Low
12/23/14 - $3.30
Market Cap
176.3M
Average Volume 10 Days
17.8K
EPS TTM
$-0.80
Shares Outstanding
34.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AURIS MEDICAL AG (EARS)

Related News

No related news articles were found.

auris medical ag (EARS) Related Businessweek News

No Related Businessweek News Found

auris medical ag (EARS) Details

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

16 Employees
Last Reported Date: 05/15/15
Founded in 1998

auris medical ag (EARS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

auris medical ag (EARS) Key Developments

Auris Medical Holding AG Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Operating Expenses Guidance for the Financial Year 2015

Auris Medical Holding AG reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of CHF 7.159 million against CHF 5.858 million a year ago. Loss before tax was CHF 8.052 million against CHF 5.859 million a year ago. Net loss attributable to owners of the company was CHF 8.052 million against CHF 5.859 million a year ago. Loss per share, basic and diluted was CHF 0.28 against CHF 0.32 a year ago. Cash used in operating activities was CHF 6.336 million against CHF 4.061 million a year ago. The increase in cash used in operating activities was mainly due to higher research and development expenses, which more than offset the increase in accrued liabilities and lower general and administrative expenses. The company expects the operating expenses for the 2015 financial year to be in the range of CHF 30.0 to CHF 35.0 million, including spending on advancing the AM-111 late-stage program. This outlook is based on management’s current expectations and beliefs.

Auris Medical Holding AG to Report Q1, 2015 Results on May 28, 2015

Auris Medical Holding AG announced that they will report Q1, 2015 results at 12:00 PM, GMT Standard Time on May 28, 2015

Auris Medical Holding AG, Q1 2015 Earnings Call, May 28, 2015

Auris Medical Holding AG, Q1 2015 Earnings Call, May 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EARS:US $5.14 USD +0.28

EARS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EARS.
View Industry Companies
 

Industry Analysis

EARS

Industry Average

Valuation EARS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AURIS MEDICAL AG, please visit www.aurismedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.